Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give signed consent to take part in the study.
• People who are 18 years of age or older at the time of signing consent.
• People who have a confirmed diagnosis of multiple myeloma with measurable disease at the time of enrollment.
• People who have already received at least 3 previous treatment regimens for myeloma (each for at least 2 cycles in a row), including specific types of treatments: an immunomodulatory drug, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T cell therapy — unless those treatments were not available through local standard care (confirm with trial site).
• People whose kidneys, liver, and other organs are working well enough to meet the trial's requirements.
• People whose side effects from previous cancer treatments have either gone away completely or reduced to a mild level.
• Female participants who are not pregnant, do not plan to become pregnant, are not breastfeeding, and agree not to donate eggs during the study and for 30 days after the last dose.
• Male participants who agree to use a condom during any intercourse with someone who could become pregnant, throughout treatment and for at least 30 days after the last dose.
• Male participants who agree not to donate sperm during treatment and for 30 days after the last dose.
• People who agree not to donate blood during treatment and for 30 days after the last dose.

Who may not be able to join:

• People whose myeloma has spread to the brain or spinal cord (central nervous system).
• People who have been diagnosed with systemic light chain amyloidosis, POEMS syndrome, or myelodysplastic syndrome (MDS).
• People who have previously been treated with the study drug cemsidomide.
• People with a significant heart condition or seriously reduced heart function.
• People who have had a blood clot (such as a deep vein thrombosis or pulmonary embolism) within the 3 months before enrolling.
• People who have had another type of cancer (other than multiple myeloma) that has come back or required treatment within the past 3 years.
• People who have an active bacterial, fungal, or viral infection that is not under control.
• People who are unable to swallow tablets or have significant difficulty doing so.

Important: Always verify eligibility with the trial site directly before applying.